candesartan has been researched along with Chronic Illness in 50 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the change in weight over 6 months in 6933 patients in the Candesartan in Heart failure: Reduction in Mortality and morbidity (CHARM) programme, and its association with subsequent mortality (1435 deaths) over a median 32." | 9.13 | Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. ( Anker, SD; Dobson, J; Granger, CB; McMurray, JJ; Michelson, EL; Ostergren, J; Pfeffer, MA; Pocock, SJ; Solomon, SD; Swedberg, KB; Yusuf, S, 2008) |
| "Candesartan has a favorable effect on large artery function in patients with chronic heart failure." | 9.12 | Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. ( Arnold, JM; Desai, SS; Dunlap, ME; Granger, CB; Marchiori, G; Mitchell, GF; O'Brien, TX; Pfeffer, MA; Warner, E, 2006) |
| "We assessed the risk of adverse cardiovascular (CV) outcomes associated with atrial fibrillation (AF) in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program, which enrolled patients with chronic heart failure (CHF) and a broad range of ejection fractions (EFs)." | 9.12 | Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. ( Ducharme, A; Granger, CB; McMurray, JJ; Michelson, EL; Olsson, LG; Pfeffer, MA; Puu, M; Swedberg, K; Yusuf, S, 2006) |
| "Twenty-eight heart failure patients, who were on stable ACE inhibitor therapy, were randomised to receive adjunctive therapy with candesartan or placebo." | 9.10 | Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress. ( Anderson, RA; Blackman, DJ; Ellis, GR; Frenneaux, MP; Jackson, SK; Lang, D; Lewis, MJ; Morris-Thurgood, J; Mumford, C; Nightingale, AK; Penney, MD; Timmins, G, 2002) |
| "Recent studies have shown candesartan to be an effective therapy for heart failure (HF) patients, producing a significant reduction in cardiovascular mortality and morbidity." | 8.85 | The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. ( McKelvie, RS, 2009) |
| " Candesartan, a long-acting angiotensin receptor antagonist, has been shown to be an effective, and well-tolerated therapy, in both the early and late phases of cardiovascular disease (prehypertension, hypertension, left ventricular hypertrophy and heart failure)." | 8.84 | Candesartan: from left ventricular hypertrophy to heart failure, a global approach. ( Barrios, V; Calderon, A; Escobar, C, 2007) |
| " We investigated whether exaggerated BPV aggravates hypertensive cardiac remodeling and function by activating inflammation and angiotensin II-mediated mechanisms." | 7.75 | Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation. ( Anegawa, T; Hirooka, Y; Ikeda, A; Imaizumi, T; Kai, H; Kajimoto, H; Kato, S; Koga, M; Kudo, H; Mifune, H; Mori, T; Takayama, N; Yasuoka, S, 2009) |
| "We recently demonstrated that both lisinopril and candesartan, an angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor blocker, respectively, attenuate pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori (WBN/Kob) rats." | 7.73 | Combination therapy with an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker synergistically suppresses chronic pancreatitis in rats. ( Ando, T; Itoh, M; Joh, T; Kuno, A; Masuda, K; Nakamura, S; Nomura, T; Ogawa, K; Ohara, H; Okamoto, T; Shirai, T; Tang, M; Yamada, T, 2005) |
| "HD candesartan was more effective in improving plasma BNP levels and cardiac function than LD in Japanese CHF patients." | 6.78 | Efficacy and safety of a 60-week treatment with candesartan in Japanese patients with mild to moderate chronic heart failure. ( Matsuzaki, M; Miyata, Y; Nakamura, K; Nakata, E; Sugiura, K; Tsutsui, H; Yamamoto, K; Yano, M, 2013) |
| "Older patients were at a greater absolute risk of adverse CV mortality and morbidity outcomes but derived a similar relative risk reduction and, therefore, a greater absolute benefit from treatment with candesartan, despite receiving a somewhat lower mean daily dose of candesartan." | 6.73 | Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. ( Cohen-Solal, A; Granger, CB; McMurray, JJ; Michelson, EL; Pfeffer, MA; Puu, M; Solomon, SD; Swedberg, K; Yusuf, S, 2008) |
| " Considering these factors, a more individualized approach of candesartan dosing should be investigated in patients with HF." | 5.62 | Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure. ( Bonnefois, G; de Denus, S; Dubé, MP; Kassem, I; Li, J; Nekka, F; Rouleau, JL; Sanche, S; Tardif, JC; Turgeon, J; White, M, 2021) |
| "We studied 7599 patients enrolled in the candesartan in heart failure: assessment of reduction in mortality and morbidity program." | 5.20 | Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. ( Castagno, D; Claggett, B; Granger, CB; Jhund, P; McMurray, JJ; Pfeffer, MA; Skali, H; Solomon, SD; Swedberg, K; Vazir, A; Yusuf, S, 2015) |
| "We investigated the change in weight over 6 months in 6933 patients in the Candesartan in Heart failure: Reduction in Mortality and morbidity (CHARM) programme, and its association with subsequent mortality (1435 deaths) over a median 32." | 5.13 | Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. ( Anker, SD; Dobson, J; Granger, CB; McMurray, JJ; Michelson, EL; Ostergren, J; Pfeffer, MA; Pocock, SJ; Solomon, SD; Swedberg, KB; Yusuf, S, 2008) |
| "Candesartan has a favorable effect on large artery function in patients with chronic heart failure." | 5.12 | Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. ( Arnold, JM; Desai, SS; Dunlap, ME; Granger, CB; Marchiori, G; Mitchell, GF; O'Brien, TX; Pfeffer, MA; Warner, E, 2006) |
| "Japanese patients with renal insufficiency were randomly assigned to receive either an ACE inhibitor (benazepril 1." | 5.12 | A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy. ( Kanno, Y; Shoda, J; Suzuki, H, 2006) |
| "We assessed the risk of adverse cardiovascular (CV) outcomes associated with atrial fibrillation (AF) in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program, which enrolled patients with chronic heart failure (CHF) and a broad range of ejection fractions (EFs)." | 5.12 | Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. ( Ducharme, A; Granger, CB; McMurray, JJ; Michelson, EL; Olsson, LG; Pfeffer, MA; Puu, M; Swedberg, K; Yusuf, S, 2006) |
| "In a private consulting practice setting, the addition of 8 mg of Candesartan in normotensive patients with chronic renal disease and proteinuria receiving an ACEI reduced proteinuria and blood pressure." | 5.10 | Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. ( Fairley, K; Kincaid-Smith, P; Packham, D, 2002) |
| "Twenty-eight heart failure patients, who were on stable ACE inhibitor therapy, were randomised to receive adjunctive therapy with candesartan or placebo." | 5.10 | Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress. ( Anderson, RA; Blackman, DJ; Ellis, GR; Frenneaux, MP; Jackson, SK; Lang, D; Lewis, MJ; Morris-Thurgood, J; Mumford, C; Nightingale, AK; Penney, MD; Timmins, G, 2002) |
| "Recent studies have shown candesartan to be an effective therapy for heart failure (HF) patients, producing a significant reduction in cardiovascular mortality and morbidity." | 4.85 | The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. ( McKelvie, RS, 2009) |
| " Candesartan, a long-acting angiotensin receptor antagonist, has been shown to be an effective, and well-tolerated therapy, in both the early and late phases of cardiovascular disease (prehypertension, hypertension, left ventricular hypertrophy and heart failure)." | 4.84 | Candesartan: from left ventricular hypertrophy to heart failure, a global approach. ( Barrios, V; Calderon, A; Escobar, C, 2007) |
| "CHARM (candesartan in heart failure assessment of reduction in mortality and morbidity) is the largest trial program in chronic heart failure." | 4.82 | [CHARM study--new strategy for the treatment of heart failure]. ( Hasegawa, H; Komuro, I, 2004) |
| "To investigate the neuroprotective effect of candesartan, an angiotensin II type 1 receptor (AT1-R) blocker, against the neurotoxicity of the retinal ganglion cells (RGCs) in an animal model of glaucoma." | 3.75 | Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of chronic glaucoma. ( Fukuda, K; Hirooka, K; Shiraga, F; Yang, H, 2009) |
| "UACR was measured at baseline and during follow-up of 2310 patients in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Programme." | 3.75 | Albuminuria in chronic heart failure: prevalence and prognostic importance. ( Gerstein, HC; Granger, CB; Jackson, CE; McMurray, JJ; Michelson, EL; Olofsson, B; Pfeffer, MA; Solomon, SD; Swedberg, K; Yusuf, S; Zetterstrand, S, 2009) |
| " We investigated whether exaggerated BPV aggravates hypertensive cardiac remodeling and function by activating inflammation and angiotensin II-mediated mechanisms." | 3.75 | Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation. ( Anegawa, T; Hirooka, Y; Ikeda, A; Imaizumi, T; Kai, H; Kajimoto, H; Kato, S; Koga, M; Kudo, H; Mifune, H; Mori, T; Takayama, N; Yasuoka, S, 2009) |
| "We recently demonstrated that both lisinopril and candesartan, an angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor blocker, respectively, attenuate pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori (WBN/Kob) rats." | 3.73 | Combination therapy with an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker synergistically suppresses chronic pancreatitis in rats. ( Ando, T; Itoh, M; Joh, T; Kuno, A; Masuda, K; Nakamura, S; Nomura, T; Ogawa, K; Ohara, H; Okamoto, T; Shirai, T; Tang, M; Yamada, T, 2005) |
| "5-year prospective study compared the effects of angiotensin II receptor blocker, candesartan(n = 21), and ACE inhibitor(ACEI, n = 23) on proteinuria and renal function in patients with moderate renal impairment due to chronic glomerulonephritis." | 3.71 | [Comparison of ARB and ACEI for renoprotection in chronic glomerulonephritis]. ( Iigaya, K; Imai, M; Kumagai, H; Matsuura, T; Onami, T; Sakata, K; Saruta, T, 2002) |
| "HD candesartan was more effective in improving plasma BNP levels and cardiac function than LD in Japanese CHF patients." | 2.78 | Efficacy and safety of a 60-week treatment with candesartan in Japanese patients with mild to moderate chronic heart failure. ( Matsuzaki, M; Miyata, Y; Nakamura, K; Nakata, E; Sugiura, K; Tsutsui, H; Yamamoto, K; Yano, M, 2013) |
| "Older patients were at a greater absolute risk of adverse CV mortality and morbidity outcomes but derived a similar relative risk reduction and, therefore, a greater absolute benefit from treatment with candesartan, despite receiving a somewhat lower mean daily dose of candesartan." | 2.73 | Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. ( Cohen-Solal, A; Granger, CB; McMurray, JJ; Michelson, EL; Pfeffer, MA; Puu, M; Solomon, SD; Swedberg, K; Yusuf, S, 2008) |
| " Considering these factors, a more individualized approach of candesartan dosing should be investigated in patients with HF." | 1.62 | Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure. ( Bonnefois, G; de Denus, S; Dubé, MP; Kassem, I; Li, J; Nekka, F; Rouleau, JL; Sanche, S; Tardif, JC; Turgeon, J; White, M, 2021) |
| "Amiodarone was administered orally in a dose of 200 mg/body per day for the initial 7 days followed by 100 mg for the following 21 days (n = 7)." | 1.34 | In vivo electropharmacological effects of amiodarone and candesartan on atria of chronic atrioventricular block dogs. ( Aonuma, K; Matsumoto, M; Nakamura, Y; Sugiyama, A; Takahara, A; Wang, K, 2007) |
| "Candesartan was administered orally (10 mg/kg/day) for one week before rapid pacing and was continued for five weeks." | 1.32 | Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. ( Arakawa, K; Gondo, N; Kumagai, K; Nakashima, H; Saku, K; Urata, H, 2003) |
| "Candesartan treatment ameliorated the glomerular morphological findings at six weeks after disease induction." | 1.31 | Fractalkine expression and the recruitment of CX3CR1+ cells in the prolonged mesangial proliferative glomerulonephritis. ( Gejyo, F; Ikezumi, Y; Ito, Y; Kawachi, H; Koike, H; Morioka, Y; Nakamura, T; Nakatsue, T; Natori, Y; Oyanagi, A; Shimizu, F, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (6.00) | 18.2507 |
| 2000's | 35 (70.00) | 29.6817 |
| 2010's | 9 (18.00) | 24.3611 |
| 2020's | 3 (6.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Z | 1 |
| Lindner, DP | 1 |
| Bishop, NM | 1 |
| Cipolla, MJ | 1 |
| Chen, MJ | 1 |
| Wei, YJ | 1 |
| Dong, XX | 1 |
| Liu, JY | 1 |
| Chen, QY | 1 |
| Zhang, GX | 1 |
| Kassem, I | 1 |
| Sanche, S | 1 |
| Li, J | 1 |
| Bonnefois, G | 1 |
| Dubé, MP | 1 |
| Rouleau, JL | 1 |
| Tardif, JC | 1 |
| White, M | 1 |
| Turgeon, J | 1 |
| Nekka, F | 1 |
| de Denus, S | 1 |
| Matsuzaki, M | 1 |
| Yamamoto, K | 1 |
| Yano, M | 1 |
| Nakamura, K | 1 |
| Miyata, Y | 1 |
| Sugiura, K | 1 |
| Nakata, E | 1 |
| Tsutsui, H | 1 |
| Sato, Y | 1 |
| Vazir, A | 1 |
| Claggett, B | 1 |
| Jhund, P | 1 |
| Castagno, D | 1 |
| Skali, H | 1 |
| Yusuf, S | 7 |
| Swedberg, K | 8 |
| Granger, CB | 8 |
| McMurray, JJ | 8 |
| Pfeffer, MA | 7 |
| Solomon, SD | 6 |
| Pocock, SJ | 1 |
| Dobson, J | 2 |
| Michelson, EL | 6 |
| Ostergren, J | 2 |
| Anker, SD | 1 |
| Swedberg, KB | 1 |
| Cohen-Solal, A | 2 |
| Puu, M | 2 |
| Abrahamsson, P | 1 |
| Pfeffer, M | 1 |
| Pocock, S | 1 |
| Clodi, M | 1 |
| Resl, M | 1 |
| Stelzeneder, D | 1 |
| Pacini, G | 1 |
| Tura, A | 1 |
| Mörtl, D | 1 |
| Struck, J | 1 |
| Morgenthaler, NG | 1 |
| Bergmann, A | 1 |
| Riedl, M | 1 |
| Anderwald-Stadler, M | 1 |
| Luger, A | 1 |
| Pacher, R | 1 |
| Hülsmann, M | 1 |
| McKelvie, RS | 2 |
| Saruta, T | 2 |
| Hayashi, K | 1 |
| Ogihara, T | 1 |
| Nakao, K | 1 |
| Fukui, T | 1 |
| Fukiyama, K | 1 |
| Yang, H | 1 |
| Hirooka, K | 1 |
| Fukuda, K | 1 |
| Shiraga, F | 1 |
| Jackson, CE | 1 |
| Gerstein, HC | 1 |
| Zetterstrand, S | 1 |
| Olofsson, B | 2 |
| Kudo, H | 1 |
| Kai, H | 1 |
| Kajimoto, H | 1 |
| Koga, M | 1 |
| Takayama, N | 1 |
| Mori, T | 1 |
| Ikeda, A | 1 |
| Yasuoka, S | 1 |
| Anegawa, T | 1 |
| Mifune, H | 1 |
| Kato, S | 1 |
| Hirooka, Y | 1 |
| Imaizumi, T | 1 |
| Takahara, A | 2 |
| Nakamura, Y | 2 |
| Wagatsuma, H | 1 |
| Aritomi, S | 1 |
| Nakayama, A | 1 |
| Satoh, Y | 1 |
| Akie, Y | 1 |
| Sugiyama, A | 2 |
| Frimodt-Møller, M | 1 |
| Høj Nielsen, A | 1 |
| Strandgaard, S | 1 |
| Kamper, AL | 1 |
| Suzuki, H | 3 |
| Takenaka, T | 2 |
| Baron-Menguy, C | 1 |
| Toutain, B | 1 |
| Cousin, M | 1 |
| Dumont, O | 1 |
| Guihot, AL | 1 |
| Vessières, E | 1 |
| Subra, JF | 1 |
| Custaud, MA | 1 |
| Loufrani, L | 1 |
| Henrion, D | 1 |
| Lanz, TV | 1 |
| Ding, Z | 1 |
| Ho, PP | 1 |
| Luo, J | 1 |
| Agrawal, AN | 1 |
| Srinagesh, H | 1 |
| Axtell, R | 1 |
| Zhang, H | 1 |
| Platten, M | 1 |
| Wyss-Coray, T | 1 |
| Steinman, L | 1 |
| Desai, RJ | 1 |
| Ashton, CM | 1 |
| Deswal, A | 1 |
| Morgan, RO | 1 |
| Mehta, HB | 1 |
| Chen, H | 1 |
| Aparasu, RR | 1 |
| Johnson, ML | 1 |
| Suzuki, O | 1 |
| Ishii, H | 1 |
| Kobayashi, S | 2 |
| Kumagai, H | 1 |
| Sakata, K | 1 |
| Matsuura, T | 1 |
| Imai, M | 1 |
| Onami, T | 1 |
| Iigaya, K | 1 |
| Kumagai, K | 1 |
| Nakashima, H | 1 |
| Urata, H | 1 |
| Gondo, N | 1 |
| Arakawa, K | 1 |
| Saku, K | 1 |
| Gschwend, S | 1 |
| Henning, RH | 1 |
| Pinto, YM | 1 |
| de Zeeuw, D | 1 |
| van Gilst, WH | 1 |
| Buikema, H | 1 |
| Hasegawa, H | 1 |
| Komuro, I | 2 |
| Kochsiek, K | 1 |
| Fuchs, SA | 1 |
| Meyboom, RH | 1 |
| van Puijenbroek, EP | 1 |
| Guchelaar, HJ | 1 |
| Young, JB | 1 |
| Dunlap, ME | 2 |
| Probstfield, JL | 1 |
| Dietz, R | 1 |
| Hradec, J | 1 |
| Kuch, J | 1 |
| Held, P | 1 |
| Yamada, T | 1 |
| Kuno, A | 1 |
| Ogawa, K | 1 |
| Tang, M | 1 |
| Masuda, K | 1 |
| Nakamura, S | 1 |
| Ando, T | 1 |
| Okamoto, T | 1 |
| Ohara, H | 1 |
| Nomura, T | 1 |
| Joh, T | 1 |
| Shirai, T | 1 |
| Itoh, M | 1 |
| Mitchell, GF | 1 |
| Arnold, JM | 1 |
| O'Brien, TX | 1 |
| Marchiori, G | 1 |
| Warner, E | 1 |
| Desai, SS | 1 |
| Barrios Alonso, V | 1 |
| Escobar Cervantes, C | 1 |
| Calderón Montero, A | 1 |
| Shoda, J | 1 |
| Kanno, Y | 2 |
| Olsson, LG | 1 |
| Ducharme, A | 1 |
| Lutz, J | 1 |
| Risch, K | 1 |
| Liu, S | 1 |
| Antus, B | 1 |
| Schmaderer, C | 1 |
| Roos, M | 1 |
| Ouyang, N | 1 |
| Lehmann, M | 1 |
| Heemann, U | 1 |
| Komajda, M | 1 |
| Wang, K | 1 |
| Aonuma, K | 1 |
| Matsumoto, M | 1 |
| Kamei, K | 1 |
| Nakagawa, A | 1 |
| Otsuka, Y | 1 |
| Nakayama, M | 1 |
| Matsuoka, K | 1 |
| Iijima, K | 1 |
| Kudo, Y | 1 |
| Akazawa, H | 1 |
| Nakamura, T | 2 |
| Gremmler, B | 1 |
| Kisters, K | 1 |
| Kunert, M | 1 |
| Schleiting, H | 1 |
| Ulbricht, LJ | 1 |
| Barrios, V | 1 |
| Escobar, C | 1 |
| Calderon, A | 1 |
| Liu, Y | 1 |
| Tsuchihashi, T | 1 |
| Kagiyama, S | 1 |
| Matsumura, K | 1 |
| Abe, I | 1 |
| Fujishima, M | 1 |
| Taal, MW | 1 |
| Brenner, BM | 1 |
| Kurokawa, K | 1 |
| Kincaid-Smith, P | 1 |
| Fairley, K | 1 |
| Packham, D | 1 |
| Ellis, GR | 1 |
| Nightingale, AK | 1 |
| Blackman, DJ | 1 |
| Anderson, RA | 1 |
| Mumford, C | 1 |
| Timmins, G | 1 |
| Lang, D | 1 |
| Jackson, SK | 1 |
| Penney, MD | 1 |
| Lewis, MJ | 1 |
| Frenneaux, MP | 1 |
| Morris-Thurgood, J | 1 |
| Ito, Y | 1 |
| Kawachi, H | 1 |
| Morioka, Y | 1 |
| Nakatsue, T | 1 |
| Koike, H | 1 |
| Ikezumi, Y | 1 |
| Oyanagi, A | 1 |
| Natori, Y | 2 |
| Gejyo, F | 1 |
| Shimizu, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2/3 Study of Effect of AT1RB Versus ACE Inhibitor in Addition to XO Inhibitor on Progression of LV Remodeling and Dysfunction in Diabetic Patients With Acute MI.[NCT01052272] | Phase 2/Phase 3 | 72 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
LVEF is a calculation of heart pump function determined from the volume after complete filling minus the volume after complete contraction divided by the volume after complete filling. A value of 55% or greater is normal. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 56.36 | 56.82 | 42.62 | 52.37 | 39.88 | 56.33 | NA | 51.70 | 54.17 |
| Candesartan Cilexetil and Allopurinol | 52.68 | 57.28 | NA | 56.11 | 54.46 | 57.82 | 56.17 | 55.79 | 54.40 |
| Ramipril | 52.19 | 54.20 | 64.98 | 52.76 | 52.13 | 55.02 | 51.27 | 57.18 | 50.73 |
| Ramipril and Allopurinol | 53.37 | 52.80 | NA | 51.74 | 34.89 | 54.05 | NA | 55.59 | NA |
LVEDV/BSA: As an indicator of heart size, the blood volume of the heart is related to the body size. The relation of heart blood volume to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Diastolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 78.06 | 78.60 | 93.57 | 85.44 | 90.20 | 82.74 | NA | 84.28 | 76.65 |
| Candesartan Cilexetil and Allopurinol | 79.03 | 78.01 | NA | 79.75 | 63.1 | 84.95 | 75.27 | 79.72 | 75.05 |
| Ramipril | 73.03 | 74.10 | 73.23 | 75.34 | 81.19 | 75.28 | 71.99 | 70.46 | 48.68 |
| Ramipril and Allopurinol | 78.52 | 86.13 | NA | 83.95 | 108.25 | 67.96 | NA | 71.63 | NA |
LVESV/BSA: The end systolic volume is the blood volume of the heart at the end of contraction and is an index of the pump function of the heart. This relation to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 35.26 | 35.26 | 53.87 | 42.27 | 54.04 | 37.76 | NA | 41.72 | 35.13 |
| Candesartan Cilexetil and Allopurinol | 39.49 | 34.15 | NA | 36.07 | 28.74 | 37.18 | 32.99 | 35.99 | 34.22 |
| Ramipril | 36.20 | 34.77 | 25.64 | 36.82 | 39.42 | 35.30 | 35.23 | 31.17 | 23.98 |
| Ramipril and Allopurinol | 37.91 | 42.88 | NA | 42.34 | 70.48 | 30.39 | NA | 31.56 | NA |
LVED Mass/LVEDV: As an indicator of heart muscle mass and heart blood volume, the mass indexed to end diastolic volume determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a three-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Geometry. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | g/ml (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 0.95 | 0.83 | 0.67 | 0.78 | 0.70 | 0.79 | NA | 0.80 | 0.64 |
| Candesartan Cilexetil and Allopurinol | 0.87 | 0.82 | NA | 0.86 | 0.68 | 0.80 | 0.69 | 0.82 | 0.69 |
| Ramipril | 0.92 | 0.87 | 0.75 | 0.84 | 0.81 | 0.79 | 0.95 | 0.84 | 0.93 |
| Ramipril and Allopurinol | 0.86 | 0.71 | NA | 0.72 | 0.57 | 0.83 | NA | 0.80 | NA |
LVED Radius/Wall thickness As an indicator of heart muscle mass and heart volume chamber diameter, the end-diastolic radius indexed to end diastolic wall thickness determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a two-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Geometry. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | unitless (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 3.14 | 3.39 | 4.14 | 3.68 | 4.10 | 3.71 | NA | 3.58 | 4.04 |
| Candesartan Cilexetil and Allopurinol | 3.45 | 3.63 | NA | 3.42 | 3.90 | 3.56 | 4.24 | 3.56 | 4.29 |
| Ramipril | 3.23 | 3.32 | 3.42 | 3.43 | 3.44 | 3.60 | 2.92 | 3.46 | 3.12 |
| Ramipril and Allopurinol | 3.57 | 4.04 | NA | 4.01 | 4.57 | 3.60 | NA | 3.61 | NA |
By identifying three points in three different planes in the heart muscle, the maximum shortening is the average of the difference between the distance between these three points at the end of filling of the heart and the end of contraction divided by the length at the end of filling times 100. The maximum shortening is a three dimensional analysis. The higher values indicate a healthy heart. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent of length at end of filling (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,17,18) | Month 6(n=14,11,10,12) | Month 9(n=1,2,0,0) | Month 12(n=11,11,10,10) | Month 15(n=3,2,1,1) | Month 18(n=10,12,7,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 16.68 | 17.50 | 19.08 | 17.13 | 16.28 | 17.55 | NA | 16.62 | 20.38 |
| Candesartan Cilexetil and Allopurinol | 16.00 | 18.50 | NA | 18.51 | 16.36 | 17.52 | 17.89 | 17.85 | 16.59 |
| Ramipril | 15.81 | 16.88 | 18.43 | 14.57 | 17.06 | 17.26 | 16.68 | 15.67 | 13.70 |
| Ramipril and Allopurinol | 15.84 | 18.72 | NA | 17.96 | 14.22 | 17.46 | NA | 17.52 | NA |
The Peak Early Filling Rate Normalized to EDV is calculated from the slope of the volume during the early filling of the heart with respect to time. The higher values indicate a very healthy heart muscle and lower values are indicative of a very stiff muscle. This is a measure of LV Diastolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | 1/sec (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 2.01 | 2.02 | 1.13 | 1.90 | 1.48 | 1.93 | NA | 1.65 | 1.10 |
| Candesartan Cilexetil and Allopurinol | 2.0 | 1.98 | NA | 1.77 | 2.28 | 2.05 | 2.50 | 1.82 | 2.15 |
| Ramipril | 1.93 | 1.74 | 2.50 | 1.80 | 2.02 | 1.91 | 1.69 | 2.05 | 1.34 |
| Ramipril and Allopurinol | 2.11 | 2.03 | NA | 1.93 | 1.56 | 1.89 | NA | 1.88 | NA |
8 reviews available for candesartan and Chronic Illness
| Article | Year |
|---|---|
The CHARM program: the effects of candesartan for the management of patients with chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Female | 2009 |
[Recent clinical evidences of RAS inhibitors on chronic kidney diseases].
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimida | 2010 |
[CHARM study--new strategy for the treatment of heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2004 |
[ARB II in chronic heart failure. Coincidences and divergences. Class effect?].
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Heart | 2005 |
Improving outcomes in chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Agents; | 2006 |
[Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2007 |
Candesartan: from left ventricular hypertrophy to heart failure, a global approach.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2007 |
ACE-I vs angiotensin II receptor antagonists: prevention of renal injury in chronic rat models.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1999 |
17 trials available for candesartan and Chronic Illness
| Article | Year |
|---|---|
Efficacy and safety of a 60-week treatment with candesartan in Japanese patients with mild to moderate chronic heart failure.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Asian People; Benzimidazole | 2013 |
Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Chronic Disease; | 2015 |
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2008 |
Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
Topics: Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blocke | 2008 |
Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure.
Topics: Acute Coronary Syndrome; Age Distribution; Aged; Aged, 80 and over; Angina, Unstable; Angiotensin II | 2009 |
Interactions of glucose metabolism and chronic heart failure.
Topics: Benzimidazoles; Benzoates; Biomarkers; Biphenyl Compounds; Blood Glucose; Blood Pressure; Chronic Di | 2009 |
Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood | 2009 |
Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazo | 2010 |
[Angiotensin receptor blockers in heart failure. CHARM Study].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2004 |
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiac Output, L | 2004 |
Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Aorta; Benzimidazoles; Biphenyl Co | 2006 |
A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Ben | 2006 |
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biphenyl Compoun | 2006 |
Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2006 |
Effects of different AT1-receptor antagonists in the therapy of severe heart failure pretreated with ACE inhibitors.
Topics: Acrylates; Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-C | 2007 |
Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazo | 2002 |
Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biph | 2002 |
25 other studies available for candesartan and Chronic Illness
| Article | Year |
|---|---|
ACE (Angiotensin-Converting Enzyme) Inhibition Reverses Vasoconstriction and Impaired Dilation of Pial Collaterals in Chronic Hypertension.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compound | 2020 |
The effect of candesartan on chronic stress induced imbalance of glucose homeostasis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; | 2020 |
Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure.
Topics: Administration, Oral; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biological Vari | 2021 |
Angiotensin II receptor blockers for patients with chronic heart failure: the next step forward.
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Heart Failure | 2013 |
Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of chronic glaucoma.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2009 |
Albuminuria in chronic heart failure: prevalence and prognostic importance.
Topics: Age Distribution; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphen | 2009 |
Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Benzimidazoles; B | 2009 |
Long-term blockade of L/N-type Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart.
Topics: Action Potentials; Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atr | 2009 |
Involvement of angiotensin II in the remodeling induced by a chronic decrease in blood flow in rat mesenteric resistance arteries.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2010 |
Angiotensin II sustains brain inflammation in mice via TGF-beta.
Topics: Angiotensin II; Animals; Benzimidazoles; Biphenyl Compounds; Cells, Cultured; Chronic Disease; Encep | 2010 |
Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure.
Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Confoun | 2012 |
Effects of an angiotensin 2 receptor blocker plus diuretic combination drug in chronic heart failure complicated by hypertension.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; | 2011 |
[Comparison of ARB and ACEI for renoprotection in chronic glomerulonephritis].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl | 2002 |
Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Atrial Fibrillation; Benzimidazo | 2003 |
Myogenic constriction is increased in mesenteric resistance arteries from rats with chronic heart failure: instantaneous counteraction by acute AT1 receptor blockade.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2003 |
Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2004 |
Use of angiotensin receptor antagonists in patients with ACE inhibitor induced angioedema.
Topics: Adverse Drug Reaction Reporting Systems; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-C | 2004 |
Combination therapy with an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker synergistically suppresses chronic pancreatitis in rats.
Topics: Actins; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazol | 2005 |
Angiotensin type 1 and type 2 receptor blockade in chronic allograft nephropathy.
Topics: Angiotensin Receptor Antagonists; Animals; Apoptosis; Benzimidazoles; Biphenyl Compounds; Chronic Di | 2006 |
In vivo electropharmacological effects of amiodarone and candesartan on atria of chronic atrioventricular block dogs.
Topics: Amiodarone; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Arrhythmia Agents; Benzimidazoles | 2007 |
Heart failure management. Interview with Karl Swedberg.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2007 |
Chronic glomerulonephritis associated with IgG subclass deficiency.
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents; Benzimidazoles | 2007 |
Central and peripheral mechanisms involved in hypertension induced by chronic inhibition of nitric oxide synthase in rats.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Anima | 1998 |
Effects of candesartan on the proteinuria of chronic glomerulonephritis.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Arterioles; Benzimidazoles; | 1999 |
Fractalkine expression and the recruitment of CX3CR1+ cells in the prolonged mesangial proliferative glomerulonephritis.
Topics: Animals; Antibodies, Monoclonal; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Chemok | 2002 |